Clinical Trials Browser

Recurrence × Bortezomib × 30 days × Clear all

NCT05572515 2026-04-13

MajesTEC-9

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05519085 2026-03-24

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 1/2 Active not recruiting

466 enrolled 57 charts

Multiple Myeloma, Recurrence